PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :
C07H 21/00, C07K 3/00, 5/04
C07K 7/52, 13/00, 15/06
C12N 5/10, 5/21, 5/31
C12P 21/02, G01N 33/53, 33/532
G01N 33/536, 33/537, 33/538
G01N 33/541, 33/543, 33/544
G01N 33/68

A1

(11) International Publication Number: **WO 93/08208**

(43) International Publication Date: 29 April 1993 (29.04.93)

(21) International Application Number: PCT/US92/09199

(22) International Filing Date: 21 October 1992 (21.10.92)

(30) Priority data:
779,704 21 October 1991 (21.10.91) US

(71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, One Abbott Park Road, Abbott Park, IL 60064-3500 (US).

(72) Inventors: ROBINSON, John, M. ; 4998 Oak Lane, Gurnee, IL 60031 (US). PILOT-MATIAS, Tami, J. ; 2100 Cranbrook Road, Libertyville, IL 60048 (US). HUNT, Jeffrey, C. ; 844 Paine Avenue, Lindenhurst, IL 60046 (US).

(74) Agents: GORMAN, Edward, H., Jr. et al.; Abbott Laboratories, CHAD 0377 AP6D-2, One Abbott Park Road, Abbott Park, IL 60064-3500 (US).

(81) Designated States: AU, CA, JP, KR, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE).

Published
With international search report.

(54) Title: BORRELIA BURGDORFERI ANTIGENS AND USES THEREOF

(57) Abstract

This invention relates generally to an assay for Lyme disease which detects the antibody to *Borrelia burgdorferi*, the causative agent of Lyme disease. More specifically, the assay employs antigens derived from amino acid regions in the flagellum of *Borrelia burgdorferi*. These antigens are immunoreactive with antibodies to *Borrelia burgdorferi* but are not substantially immunoreactive with antibodies to *Treponema pallidum*, the syphilis causing agent. DNA sequences of the antigens, clones and vectors containing the DNA sequences are also disclosed. Polypeptides derived therefrom can be used as reagents for the detection of antibody to *Borrelia burgdorferi* in the body fluids from individuals with Lyme disease.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo			SE	Sweden
CH	Switzerland	KR	Republic of Korea	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

BORRELIA BURGDORFERI ANTIGENS AND USES THEREOF

DESCRIPTION OF THE BACKGROUND ART

Lyme disease is a multisystem illness caused by the tick-transmitted spirochete Borrelia burgdorferi (hereinafter referred to as "B. burgdorferi") (Burgdorfer, et al. 1982. Science 216:1317-1319; Steere, et al. 1983. N Engl J Med 308:733-740). Lyme borreliosis is the most common arthropod-borne infection in the United States and has been reported in many countries throughout Asia and Europe (Steere 1989. N Engl J Med 1:586-596). The early feature of the disease is a local infection of the skin, which may be followed by the development of systemic disease involving the nervous system, heart and joints (Steere 1989. N Engl J Med 1:586-596).

Culture of the spirochete from human body fluids and antigen detection methods often are falsely negative in the diagnosis of Lyme disease (Steere, et al. 1983. N Engl J Med 308:733-740; Benach, et al. 1983 N Engl J Med 308:740-742), leaving serological methods for antibodies to B. burgdorferi as the most appropriate currently available means for diagnosis. Most current diagnostic assays for Lyme disease utilize whole or sonicated B. burgdorferi cells as the test antigen, although many investigators have demonstrated improved performance of these tests when subcellular fractions of the spirochete were used (Grodzicki, et al. 1988. J Infect Dis 157:790-797; Magnareli, et al. 1989. J Infect Dis 159:43-49; Karlsson, et al. 1990. Eur J Clin Microbiol Infect Dis 9:169-177).

The flagellar protein is an immunodominant protein that generally elicits the earliest immune response after infection (Craft, et al. 1986. Clin Invest 78:934-939; Dattwyler, et al. 1989. Rev Infect Dis 11:1494-1498). Flagellin-enriched fractions of B. burgdorferi have been shown to improve the performance of Lyme diagnostic assays (Hansen, et al. 1988. J Clin Microbiol 26:338-346). The specificity of these assays, however, may be reduced because of cross-reactivity of B. burgdorferi flagellum with the flagella of other spirochetes, most notably with Treponema pallidum (hereinafter referred to as "T. pallidum"), the causative agent of syphilis (Magnarelli, et al. 1987. J Infect Dis 156:183-188). Current Lyme disease immunoassays utilize solubilized B. burgdorferi as the source of antigen, leading to false positive reactions from individuals with certain conditions, including syphilis, leptospirosis and other spirochetal infections. The lack of specificity is due to the fact that these organisms express similar antigens, especially the highly conserved flagellin protein. Thus, most Lyme disease immunoassays suffer from false positive reactions when syphilis positive patients are analyzed. Many institutions determine syphilis serologic status on all Lyme positive patients; if they are positive for syphilis they are considered to be negative for Lyme disease. This cross-reactivity with syphilis patients can be reduced by adsorption of the patient sera with the Reiter strain of Treponema (Magnarelli, et al. 1990. J Clin Microbiol 28:1276-1279), but this decreases the sensitivity of Lyme diagnostic assays.

The nucleotide and amino acid sequences have been determined for the flagellin protein of several B. burgdorferi isolates (Gassmann, et al. 1989. Nucleic Acids Res 17:3590; Wallich, et al. 1990. Infect Immun 58:1711-1719; Gassmann, et al. 1991 J Bacteriol 173:1452-1459; Collins, et al. 1991. Infect Immun 59:514-520). The entire flagellin protein contains 336 amino acids. Comparison of the conserved sequences with that of the T. pallidum endoflagellar protein (Pallesen, et al. 1989. Infect Immun 57:2166-2172) indicated high sequence homology at each end of the protein, but more variability in the central region. Collins, et al demonstrated that antibodies in the sera of Lyme and arthritis patients bound exclusively at the common amino-terminal region of the flagellin protein.

Wallich, et al., supra, merely speculated that the center region may be specific, based on comparison of amino acid sequences from similar organisms. Gassman, et al., (J. Bacteriol. 1991. 173:1452-1459) synthesized a series of overlapping octapeptides representing the entire sequence of the flagellum and analyzed serum from animals immunized with a variety of closely related bacteria. They demonstrated that the middle region from amino acid 180 to 260 only bound B. burgdorferi serum. Neither group demonstrated specificity using human sera. Significantly, Collins et al, supra observed that most Lyme patient sera bound to the amino-terminus region and their results indicated that a specific assay using flagellin was not possible.

BRIEF SUMMARY OF THE INVENTION

One aspect of the present invention presents improved immunoassays for detecting the presence of an antibody to a B. burgdorferi antigen in a sample by contacting the sample with a "differentiating polypeptide" which binds an antibody to B. burgdorferi but which does not substantially bind an antibody to T. pallidum. The sample is preferably biological fluids such as whole blood, serum, plasma, cerebral spinal fluid, or synovial fluid.

Another aspect of the invention presents the differentiating polypeptides. The differentiating polypeptides are preferably based on amino acid sequences in the B. burgdorferi flagellum, wherein the amino acid sequence is immunoreactive with antibodies to B. burgdorferi but is not substantially immunoreactive with antibodies to T. pallidum. The differentiating polypeptides are preferably produced by chemical synthesis or recombinantly. Examples of the differentiating polypeptide are: p410, p776, fusion protein p410, fusion protein p776, and equivalent polypeptides thereof. The differentiating polypeptdies may be labelled to facilitate detection in an assay.

Another aspect of the invention presents nucleotide sequences, vectors, and plasmids coding for the differentiating polypeptides, and cells transformed by these plasmids. Processes for recombinantly producing these differentiating polypeptides are also presented.

A further aspect of the invention presents assay kits utilizing the differentiating polypeptides for diagnosing Lyme disease and differentiating it from syphilis.

Other aspects and advantages of the invention will be apparent to those skilled in the art upon consideration of the following detailed description which provides illustrations of the invention in its presently preferred embodiments.

BRIEF DESCRIPTION OF DRAWINGS

Figures 1A and 1B illustrate the sequence homology between the Borrelia burgdorferi flagellar protein and the Treponema pallidum flagellar protein. The character "*" indicates the two aligned residues are identical.

Figure 2 illustrates the regions of the flagellum protein chosen for cloning and their designations.

Figure 3 illustrates the construction of plasmid pB776.

Figure 4 illustrates the expression of the CKS-flagellum proteins in E. coli.

Figure 5 illustrates the construction of plasmid pB410.

Figure 6 illustrates the construction of plasmid pBT1042.

Figure 7 illustrates the construction of plasmid pBT445.

Figure 8 illustrates the construction of plasmid pBT259.

Figure 9 illustrates the purity of the CKS-flagellum recombinant protein following purification.

Figure 10 illustrates the reactivity of the recombinant flagellar proteins with sera from patients with clinical histories of Lyme disease.

Figure 11 illustrates the reactivity of the recombinant flagellar proteins with sera from patients with syphilis disease.

DETAILED DESCRIPTION OF THE INVENTION

This invention provides for differentiating polypeptides which can increase the specificity of Lyme immunoassays without compromising their sensitivity, without the use of Treponema adsorbants, thus increasing the confidence in the results obtained. The differentiating polypeptides bind antibodies to B. burgdorferi but do not substantially bind antibodies to T. pallidum. Preferably, the differentiating polypeptides react with all Lyme positive sera that are reactive with the full length flagellin, yet do not substantially react with syphilis positive sera.

The differentiating polypeptides are preferably recombinant polypeptides that represent distinct antigenic regions of the B. burgdorferi genome. Production of these recombinant flagellin proteins can easily be scaled up to high levels. These recombinant polypeptides can be derived from the molecular cloning and expession of synthetic DNA sequences in heterologous hosts. Specifically disclosed are two recombinant proteins within the immunogenic region of the B. burgdorferi flagellum. Both proteins are expressed as chimeric fusions with the E. coli CMP-KDO synthetase (CKS) gene. The proteins are p410 and p776 expressed by plasmids pB410 and pB776 representing amino acids 137 to 262, and 64 to 311 of the B. burgdorferi sequence, respectively. Note that the terms p410, p776 will also refer to the respective fusion proteins. This invention also covers polypeptides from amino acids about 137 to 262, and 64 to 311, of the B. burgdorferi sequence, which may be prepared using other recombinant or synthetic methodologies. Other recombinant methodologies would include different expression systems. Other synthetic methodologies would include synthetic peptides and synthetic DNA sequences.

Also within the scope of the differentiating polypeptides are "equivalent polypeptides" which include: 1) fragments of p410 and p776 which retain the ability to bind B. burgdorferi antibodies and to differentiate the antibodies from antibodies to T. pallidum; 2) polypeptides which contain changes in amino acid residues of the disclosed amino acid sequences

which do not affect the polypeptides' ability to bind B. burgdorferi antibodies and to differentiate the antibodies from antibodies to T. pallidum. Generally, antibodies bind to epitopes defined by about 3 to 10 amino acids. Therefore, certain fragments of p410 and p776 are predicted to bind antibodies to B. burgdorferi more strongly than antibodies to T. pallidum. This is borne out by the comparable reactivity of the Lyme patient sera with p776 and p410, the latter being a fragment of p776. Further, minor amino acid changes in flagellin sequence occur in various B. burgdorferi strains. For example, the American strain B31 (used in the Examples of this application), sequenced by Wallich et al., supra, is different from the European strain GeHo, sequenced by Gassman, et al., supra, at residues 180 and 279. Thus, within the scope of this invention are conservative amino acid changes which do not impair the ability of the resulting polypeptide to differentiate between antibody to B. burgdorferi and antibody to T. pallidum.

The preferred recombinant polypeptides having B. burgdorferi selective antigenic epitopes were selected from portions of the B. burgdorferi flagellum sequence which possess amino acid sequences unique to this organism and which possess little homology to amino acid sequences of other organisms of infectious diseases, such as the flagellum of T. pallidum.

The polypeptides useful in the practice of this invention are preferably produced using recombinant technologies. The DNA sequences which encode the desired polypeptides are amplified

by use of the polymerase chain reaction (hereinafter referred to as "PCR"). Oligonucleotide sequences to be used as primers which can specifically bind to the ends of the regions of interest are synthesized. After the desired region of the gene has been amplified the desired sequence is incorporated into an expression vector which is transformed into a host cell. The DNA sequence is then expressed by the host cell to give the desired polypeptide which is harvested from the host cell. Plant, bacterial, yeast, insect, and mammalian expression systems may be used. Vectors which may be used in these expression systems may contain fragments of plant, bacterial, yeast, insect, viral, and/or mammalian origins.

A preferred expression method utilizes a fusion system where the recombinant B. burgdorferi proteins are expressed as a fusion protein with an E. coli enzyme, CKS (CTP:CMP-3-deoxy-manno-octulosonate cytidylyl transferase or CMP-KDO synthetase). The CKS method of protein synthesis is disclosed in published European Published Patent Application No. 331,961 to Bolling, hereby incorporated by reference.

The amplified regions of the B. burgdorferi flagellin gene are digested with appropriate restriction enzymes, ligated and cloned into the CKS fusion vector pTB210 or pTPM210. These plasmids are then transformed into competent E. coli cells. The resultant fusion proteins are under control of the lac promoter.

These differentiating polypeptides can be used for the detection of antibodies against B. burgdorferi in biological fluids. These differentiating polypeptides are preferably used in the serologic detection of Lyme disease, for example, in an enzyme immunoassay format. In an example of a direct assay, these differentiating polypeptides serve as antigens and are attached to a solid phase and then incubated with patient sera. Human serum or plasma is preferably diluted in a sample diluent before incubation. If antibodies to B. burgdorferi are present in the sample they will form an antigen-antibody complex with the differentiating polypeptides and become affixed to the solid phase.

After the antigen-antibody complex has formed, unbound materials and reagents are removed by washing the solid phase and the antigen- antibody complex is reacted with a solution containing labelled antibodies directed against human antibodies. For example, the labelled antibody can be horseradish peroxidase-labeled goat antibody. This peroxidase labeled antibody then binds to the antigen-antibody complex already affixed to the solid phase. In a final reaction the horseradish peroxidase is contacted with o-phenylenediamine and hydrogen peroxide which results in a yellow-orange color. The intensity of the color is proportional to the amount of antibody which initially binds to the differentiating polypeptide affixed to the solid phase.

Another assay format provides for an antibody-capture assay in which anti-immunoglobulin antibody on the solid phase captures the patient's antibody, which is then reacted with the differentiating polypeptide. The application of this format in the serological assay of Lyme disease using prior art antigenic materials is taught in Berardi et al. 1988. J Infect Dis 158:754-760. If antibody to B. burgdorferi is present, it captures the differentiating polypeptide, and the bound differentiating polypeptide is detected by means of labelled polyclonal or monoclonal antibodies directed against the differentiating polypeptides. The antibody-capture assay is particularly useful for and can increase the sensitivity of detection of IgM and IgG to B. burgdorferi antigens. In an example of this assay, the fluid sample is first contacted with a solid support containing a bound antibody capable of binding the mu-chain of IgM or the gamma-chain of IgG antibodies. Specific antibody is detected by reacting this with the differentiating polypeptides followed by non-human antibody to the differentiating polypeptides. The non-human antibody is generally labelled for detection. It is believed that this antibody-capture immunoassay format will have increased sensitivity, especially for IgM. Alternatively, one can forego the non-human antibody and instead label the differentiating polypeptides for direct detection.

Antibodies to the differentiating polypeptides for use in the above capture assay can be produced using standard procedures known in the arts. For example, antibodies can be produced by

innoculating a host animal such as a rabbit, rat, goat, mouse etc., with the differentiating polypeptides or fragments thereof. Before innoculation, the polypeptides or fragments may be first conjugated with keyhole limpet hemocyanin (KLH) or bovine serum albumin (BSA). After an appropriate time period for the animal to produce antibodies to the polypeptides or fragments, the anti-serum of the animal is collected and the polyclonal antibodies separated from the anti-serum using techniques known in the art. Monoclonal antibodies can be produced by the method described in Kohler and Milstein (Nature, 1975. 256: 495-497) by immortalizing spleen cells from an animal inoculated with the polypeptides or fragments thereof. The immortalization of the spleen cell is usually conducted by fusing the cell with an immortal cell line, for example, a myeloma cell line, of the same or different species as the innoculated animal. The immortalized fused cell can then be cloned and the cell screened for production of the desired antibody.

Another assay format provides for an immunodot assay for identifying the presence of an antibody that is immunologically reactive with a B. burgdorferi antigen by contacting a sample with differentiating polypeptides from B. burgdorferi bound to a solid support under conditions suitable for complexing the antibody with the differentiating polypeptides and detecting the antibody-differentiating polypeptide complex by reacting the complex.

Suitable methods and reagents for detecting an antibody-antigen complex in an assay of the present invention are commercially available or known in the relevant art. For example, the detector antibodies or differentiating polypeptides may be labelled with enzymatic, radioisotopic, fluorescent, luminescent, or chemiluminescent label. These labels may be used in hapten-labelled antihapten detection systems according to known procedures, for example, a biotin-labelled antibiotin system may be used to detect an antibody-antigen complex.

In all of the assays, the sample is preferably diluted before contacting the polypeptide absorbed on a solid support. The samples may be biological fluids such as whole blood, serum, plasma, cerebral spinal fluid, or synovial fluid. Solid support materials may include cellulose materials, such as paper and nitrocellulose; natural and synthetic polymeric materials, such as polyacrylamide, polystyrene, and cotton; porous gels such as silica gel, agarose, dextran and gelatin; and inorganic materials such as deactivated alumina, magnesium sulfate and glass. Suitable solid support materials may be used in assays in a variety of well known physical configurations, including microtiter wells, test tubes, beads, strips, membranes, and microparticles. A preferred solid support for a non-immunodot assay is a polystyrene microwell, polystyrene beads, or polystyrene microparticles. A preferred solid support for an immunodot assay is nitrocellulose or paper.

The present invention also encompasses assay kits containing differentiating polypeptides in a concentration suitable for use in immunoassay. In the kits, the differentiating polypeptides may be bound to a solid support and where needed, the kits may include sample preparation reagents, wash reagents, detection reagents and signal producing reagents.

The nucleotide sequences which code for these proteins are also described. Since nucleotide codons are redundant, also within the scope of this invention are equivalent nucleotide sequences which include: nucleotide sequences which code for the same proteins or equivalent proteins. Also within the scope of the invention are fragments and variations of the nucleotide sequences of SEQ ID NO: 3 and SEQ ID NO: 7, which are capable of coding for a polypeptide which is immunoreactive with an antibody to B. burgdorferi but not substantially immunoreactive with an antibody to T. pallidum.

The synthesis, cloning, and characterization of the recombinant polypeptides as well as the preferred formats for assays using these polypeptides are provided in the following examples.

EXAMPLES

REAGENTS AND ENZYMES

Restriction enzymes, T4 DNA ligase, nucleic acid molecular weight standards, X-gal

(5-bromo-4-chloro-,3-indonyl-ß-Dgalactoside), and IPTG (isopropyl-ß-D-thiogalactoside), were purchased from New England Biolabs, Inc., Beverly, Massachusetts; or Bethesda Research Laboratories Life Technologies, Inc., Gaithersburg. Maryland. Prestained protein molecular weight standards were purchased from Diversified Biotech, Newton Centre, Massachusetts. Acrylamide, N-N'-methylene-bis-acrylamide; N,N,N',N',- Tetramethylethylenediamine (TEMED), horseradish peroxidase labeled secondary antibodies, and sodium dodecylsulfate were purchased from BioRad Laboratories, Richmond, California. Lysozyme, ampicillin, and tetracycline were obtained from Sigma Chemical Co., St. Louis, Missouri.

Superbroth contained 32 gram/L tryptone, 20 gram/L yeast extract, 5 gram/L NaCl, pH 7.4. SDS/PAGE loading buffer consisted of 62.5mM Tris, pH6.8, 2% SDS, 10% glycerol, 5% 2-mercaptoethanol, and 0.1 mg/ml bromophenol blue. Sonication buffer contained 50mM Tris, pH8.0, 50mM NaCl, and 1 mM EDTA, Blocking solution consisted of 5% Carnation nonfat dry milk in Tris-buffered saline.

BSKII medium was prepared according to Barbour 1984. Yale J Biol. Med 57:521-525.

GENERAL METHODS

All restriction enzyme digestions were performed according to suppliers' instructions. At least 5 units of enzyme were used per microgram of DNA, and sufficient incubation was allowed to complete digestion of DNA. Standard procedures were used for minicell lysate DNA preparation, phenol-chloroform extraction,

ethanol precipitation of DNA, restriction analysis of DNA on agarose, low melting agarose gel purification of DNA fragments, and ligation of DNA fragments with T4 DNA ligase (Maniatis et al., *Molecular Cloning. A Laboratory Manual* [New York: Cold Spring Harbor, 1982]).

Example 1

Cloning strategy for specific flagellar protein regions

The amino acids of the B. burgdorferi flagellar protein and the flagellar protein of T. pallidum were aligned (Fig. 1) using the PALIGN program (PC-Gene; Intelligenetics, Inc., Mountain View, CA). The T. pallidum flagellar protein has a 38% homology with the B. burgdorferi flagellum protein amino acid sequence. This homology is greatest at the amino- and carboxy-termini of each protein, providing for greater heterogeneity in the central region. The B. burgdorferi flagellar protein was divided into three regions for cloning based on this homology (Fig.2); the fragment of amino acid residues 1-137 exhibits 52% homology, the fragment of amino acids 137-262 exhibits 14% homology, and the fragment of amino acids 262-336 exhibits 53% homology with the T. pallidum flagellar protein sequence. An additional fragment, encompassing the amino acid residues 64-311 of the B. burgdorferi flagellin was chosen for cloning because it was the largest fragment with the least possible homology, exhibiting 30% homology. The common amino acid sequences between these two proteins in region pB445 (containing amino acids 1-137) and pB259 (containing amino acids 262-336)

frequently occur in stretches of up to six consecutive residues, while the common amino acid sequences in p410 (containing amino acids 137-262) and p776 (containing amino acids 64-311) are infrequently clustered. This fact is significant because an antibody can potentially recognize stretches of 6 to 8 amino acids.

EXAMPLE 2

Construction of pB776

A. Construction of Plasmids pTB210 and pTPM210

The CKS expression vector pTB210 allows the fusion of recombinant proteins to the CMP-KDO synthetase (CKS) protein. The vector consists of the plasmid pBR322 with a modified *lac* promoter fused to a *kdsB* gene fragment (encoding the first 239 of the entire 248 amino acids of the *E. coli* CMP-KDO synthetase protein), and a synthetic linker fused to the end of the *kdsB* gene fragment. The synthetic linker includes multiple restriction sites for insertion of genes, translational stop signals, and the *trpA* rho-independent transcriptional terminator. The vector pTPM210 is identical to pTB210 except for a single mutation in the *kdsB* gene. This mutation gives rise to a single amino acid change in the CKS protein sequence, Asn at position 239 rather than Asp. The CKS method of protein synthesis as well as CKS vectors including pTB210 are disclosed in European published Patent Application, No. 331,961, to Bolling, which is hereby incorporated by reference.

Preparation of B. burgdorferi DNA

DNA was isolated from a 200 ml culture of B. burgdorferi strain B31 (ATCC 35210) after 5 days of growth in BSKII medium by the following procedure: Cells were harvested at 3000 x g for 15 minutes then resuspended in 8.5 ml of 50 mM glucose, 10 mM EDTA, 25 mM Tris pH 8.0, 2 mg/ml lysozyme. After 15 minutes at room temperature, 1.25 ml of a 4:1 mixture of 20% sarkosyl:0.25 M EDTA was added and the solution was mixed gently. This was followed by addition of 9.3 grams of cesium chloride and 0.5 ml of a 5 mg/ml solution of ethidium bromide. The mixture was then centrifuged in a Beckman 70.1 Ti rotor for 40 hours at 44,000 rpm. The DNA band was isolated, extracted with NaCl saturated isopropanol to remove the ethidium bromide, then precipitated with ethanol and resuspended in 10 mM Tris, 1 mM EDTA, pH 8.0.

C. Generation of 776 bp Flagellin Gene Fragment

Oligonucleotide primers for use in the PCR amplification of the region encoding amino acids 64 to 311 of B. burgdorferi flagellin were designed based on the published sequence of the gene, and included convenient restriction endonuclease sites to be used for cloning into the CKS expression vectors. The sequences of the primers are shown here:

Sense primer:

5'-AAATAGATCTCAGACCCGAGAAATACTTCAAAGGCTAT

(BglII site is underlined) The above sequence is designated sequence identification number 9, i.e. SEQ ID NO: 9, in the accompanying sequence listing.

Antisense primer:

5'-GGGCAAGCTTATTAACTATTAGTTGTTGCTGCTAC

(HindIII site is underlined) The above sequence is designated SEQ ID NO: 10.

The following were combined in a 0.5 ml microfuge tube and subjected to the amplification cycles shown below: a mixture of 20mM $(NH_4)_2SO_4$, 80 mM Tris, and 10 mM $MgCl_2$, buffered at pH 9.0; 85 ng B. burgdorferi DNA; 60 pMol each primer; 0.4 mM each dATP, dCTP, dGTP, and dTTP; and 2.5 units Taq polymerase. The amplification cycles were 1 cycle of 97°C for 120 seconds, followed by 4 cycles of 95°C for 30 seconds, 40°C for 30 seconds, 72°C for 60 seconds, followed by 25 cycles of 95°C for 30 seconds, 65°C for 90 seconds.

D. Preparation of pB776 Expression Vector

The PCR product generated as described above was digested with BglII and HindIII and cloned into the BglII and HindIII sites of pTPM210 as shown in Fig. 3. The resultant fusion protein, CKS-776, consists of 239 amino acids of CKS, 11 amino acids contributed by linker DNA sequences, and amino acids 64 to 311 of B. burgdorferi flagellin. The DNA sequence of the region of pB776 which encodes the CKS-776 recombinant antigen as well as the encoded protein are designated SEQ ID NO: 1 and SEQ ID NO: 2, respectively. The DNA sequence of the flagellin protein region of pB776 and the encoded protein are designated SEQ ID NO: 3 and SEQ ID NO: 4, respectively.

The pB776 plasmid was transformed into competent E. coli K- 12 strain XL-1 Blue (recA1,endA1, gyrA96, thi-1, hsdR17, supE44, relA1, lac, proAB, laclqZDM15, TN10) cells obtained from Stratagene Cloning Systems, La Jolla, California. In this construction the expression of the CKS fusion protein was under the control of the lac promoter and was induced by the addition of isopropyl beta-D-thiogalactopyranoside (IPTG). The plasmid replicated as an independent element, was nonmobilizable and was maintained at approximately 10-30 copies per cell.

E. Characterization of Recombinant Flagellin 776 Fragment

In order to establish that clone pB776 expressed the CKS-776 protein, the pB776/XL-1 Blue culture was grown at 37°C in Superbroth media containing 50 mg/L ampicillin, 15 mg/L tetracycline, and 3 mM glucose. When the culture reached an OD600 of 2.0, a small sample of cells was removed. IPTG was then added to a final concentration of 1 mM to induce expression from the lac promoter. Another sample was removed after 3 hours of induction and both samples were pelleted, resuspended to an OD600 of 10 in SDS/PAGE loading buffer, and boiled for 5 minutes. Aliquots (5ul) of the prepared samples were electrophoresed on duplicate 10% SDS/PAGE gels. One gel was stained in a solution of 0.2% Coomassie blue dye in a solution of 40% methanol and 10% acetic acid for 10 minutes. Destaining was carried out using a solution of 16.5% methanol and 5% acetic acid for 3-4 hours, or until a clear background was obtained. The second gel was used for immunoblotting.

Fig. 4 presents the expression of CKS-flagellin proteins in E. coli. Lane MW contains molecular weight standards with the sizes shown on the left. The arrows on the right indicates the mobilities of the recombinant CKS-flagellin proteins. Lane 9 contains the E. coli lysate expressing CKS-776 prior to induction and lane 10 after 3 hours of induction. The results show that the recombinant protein CKS-776 has a mobility corresponding closely to the predicted molecular mass of 54,070 daltons.

Proteins from the second 10% SDS/PAGE gel were electrophoretically transferred to nitrocellulose for immunoblotting. The nitrocellulose sheet containing the transferred proteins was incubated in blocking solution for 30 minutes at room temperature followed by incubation for 1 hour at room temperature in goat anti-CKS sera which had been preblocked against E. coli cell lysate then diluted 1:2000 in blocking solution. The nitrocellulose sheet was washed two times in TBS, then incubated with HRPO-labeled rabbit anti-goat IgG, diluted 1:2000 in blocking solution. The nitrocellulose was washed two times with TBS and the color was developed in TBS containing 2 mg/ml 4-chloro-1-napthol, 0.02% hydrogen peroxide and 17% methanol. Clone pB776 demonstrated a strong immunoreactive band at approximately 54,000 daltons with the anti-CKS sera. Thus, the major protein in the pB776 three hour induced lane on the Coomassie stained gel was the major immunoreactive product as well.

EXAMPLE 3

Construction of pB410

A. Generation of 410 bp Flagellin Gene Fragment

Oligonucleotide primers for use in the PCR amplification of the region encoding amino acids 137 to 262 of B. burgdorferi flagellin were designed based on the published sequence of the gene, and included convenient restriction endonuclease sites to be used for cloning into the CKS expression vectors. The sequences of the primers are shown here:

Sense primer:

5'-AAATAGATCTCAGACCCGTCAAACAAATCTGCTTCTCA

(BglII site is underlined) The above sequence is designated SEQ ID NO: 11.

Antisense primer:

5'-GGGCAAGCTTATTAATCACTTATCATTCTAATAG

(HindIII site is underlined) The above sequence is designated SEQ ID NO: 12.

PCR was performed using these primers and B. burgdorferi DNA as described in Example 2.

B. Preparation of pB410 Expression Vector

The PCR product generated as described above was digested with BglII and HindIII and cloned into the BglII and HindIII sites of pTPM210 as shown in Fig. 5. The pB410 plasmid was transformed into competent E. coli K-12 strain XL-1 Blue as described in Example 2. The resultant fusion protein, CKS-410, consists of 239 amino acids of CKS, 11 amino acids contributed

by linker DNA sequences, and amino acids 137 to 262 of B. burgdorferi flagellin. The DNA sequence of the region from pB410 encoding the CKS-410 recombinant antigen as well as the encoded protein are designated SEQ. ID. 5 and 6 respectively. The DNA sequence from the B. burgdorferi flagellin protein and the encoded protein are designated SEQ. ID. 7 and 8 respectively.

C. Characterization of Recombinant Flagellin 410 Fragment

In order to establish that clone pB410 expressed the CKS-410 protein, the pB410/XL-1 Blue culture was grown and samples were prepared as described in Example 2. Fig. 4 presents the expression of CKS-flagellin proteins in E. coli. Lane MW contains molecular weight standards with the sizes shown on the left. The arrows on the right indicates the mobilities of the recombinant CKS-flagellin proteins. Lane 5 contains the E. coli lysate expressing CKS-410 prior to induction and lane 6 after 3 hours of induction. The results show that the recombinant protein CKS-410 has a mobility corresponding closely to the predicted molecular mass of 40,440 daltons. Clone pB410 also demonstrated a strong immunoreactive band at approximately 40,000 daltons with the anti-CKS sera when reacted as described in Example 2. Thus, the major protein in the pB410 three hour induced lane on the Coomassie stained gel was the major immunoreactive product as well.

EXAMPLE 4

Construction of pBT1042

A. Generation of 1042 bp Flagellin Gene Fragment

Oligonucleotide primers for use in the PCR amplification of the region encoding amino acids 1 to 336 of B. burgdorferi flagellin were designed based on the published sequence of the gene, and included convenient restriction endonuclease sites to be used for cloning into the CKS expression vectors. The sequences of the primers are shown below:

Sense primer:

5'-AAATAGATCTCAGACCCGATGATTATCAATCATAATAC

(BglII site is underlined) The above sequence is designated SEQ ID NO: 13.

Antisense primer:

5'-GGGCGGTACCTTATTATCTAAGCAATGACAAAAC

(KpnI site is underlined) The above sequence is designated SEQ ID NO: 14.

PCR was performed using these primers and B. burgdorferi DNA as described in Example 2.

B. Preparation of pBT1042 Expression Vector

The PCR product generated as described above was digested with BglII and KpnI and cloned into the BglII and KpnI sites of pTB210 as shown in Fig. 6. The pBT1042 plasmid was transformed into competent E. coli K-12 strain XL-1 Blue as described in Example 2. The resultant fusion protein, CKS-1042, consists of 239 amino acids of CKS, 11 amino acids contributed by linker DNA sequences, and amino acids 1 to 336 of B. burgdorferi flagellin.

C. Characterization of Recombinant Flagellin 1042 Fragment

In order to establish that clone pBT1042 expressed the CKS-1042 protein, the pBT1042/XL-1 Blue culture was grown and samples were prepared as described in Example 2. Fig. 4 presents the expression of CKS-flagellin proteins in E. coli. Lane 1 contains the E. coli lysate expressing CKS-1042 prior to induction and lane 2 after 3 hours of induction. The results show that the recombinant protein CKS-1042 has a mobility corresponding closely to the predicted molecular mass of 63,350 daltons. Clone pBT1042 also demonstrated a strong immunoreactive band at approximately 63,000 daltons with the anti-CKS sera when reacted as described in Example 2. Thus, the major protein in the pBT1042 three hour induced lane on the Coomassie stained gel was the major immunoreactive product as well.

EXAMPLE 5

Construction of pBT445

A. Generation of 445 bp Flagellin Gene Fragment

Oligonucleotide primers for use in the PCR amplification of the region encoding amino acids 1 to 137 of B. burgdorferi flagellin were designed and included convenient restriction endonuclease sites to be used for cloning into the CKS expression vectors. The sequences of the primers are shown below:

Sense primer:

5'-AAATAGATCTCAGACCCGATGATTATCAATCATAATAC

(BglII site is underlined) The above sequence is designated SEQ ID NO: 13.

Antisense primer:

5'-GGGCGGTACCTTATTATGATAACATGTGCATTTGGTT

(KpnI site is underlined) The above sequence is designated SEQ ID NO: 15.

PCR was performed using these primers and B. burgdorferi DNA as described in Example 2.

B. Preparation of pBT445 Expression Vector

The PCR product generated as described above was digested with BglII and KpnI and cloned into the BglII and KpnI sites of pTB210 as shown in Fig. 7. The pBT445 plasmid was transformed into competent E. coli K-12 strain XL-1 Blue as described in Example 2. The resultant fusion protein, CKS-445, consists of 239 amino acids of CKS, 11 amino acids contributed by linker DNA sequences, and amino acids 1 to 137 of B. burgdorferi flagellin.

C. Characterization of Recombinant Flagellin 445 Fragment

In order to establish that clone pBT445 expressed the CKS-445 protein, the pBT445/XL-1 Blue culture was grown and samples were prepared as described in Example 2. Fig. 4 presents the expression of CKS-flagellin proteins in E. coli. Lane 3 contains the E. coli lysate expressing CKS-445 prior to induction and lane 4 after 3 hours of induction. The results show that the recombinant protein CKS-445 has a mobility corresponding closely to the predicted molecular mass of 42,500 daltons. Clone pBT445 also demonstrated a strong immunoreactive band at approximately 42,000 daltons with the

anti-CKS sera when reacted as described in Example 2. Thus, the major protein in the pBT445 three hour induced lane on the Coomassie stained gel was the major immunoreactive product as well.

EXAMPLE 6

Construction of pBT259

A. Generation of 259 bp Flagellin Gene Fragment

Oligonucleotide primers for use in the PCR amplification of the region encoding amino acids 262 to 336 of *B. burgdorferi* flagellin were designed, and included convenient restriction endonuclease sites to be used for cloning into the CKS expression vectors. The sequences of the primers are shown below:

Sense primer:

5'-AAATAGATCTCAGACCCGGATCAAAGGGCAAATTTAGG

(BglII site is underlined) The above sequence is designated SEQ ID NO: 16.

Antisense primer:

5'-GGGCGGTACCTTATTATCTAAGCAATGACAAAAC

KpnI site is underlined) The above sequence is designated SEQ ID NO: 14.

PCR was performed using these primers and *B. burgdorferi* DNA as described in Example 2.

B. Preparation of pBT259 Expression Vector

The PCR product generated as described above was digested with BglII and KpnI and cloned into the BglII and KpnI sites of pTB210 as shown in Fig. 8. The pBT259 plasmid was transformed into competent *E. coli* K-12 strain XL-1 Blue as

described in Example 2. The resultant fusion protein, CKS-259, consists of 239 amino acids of CKS, 11 amino acids contributed by linker DNA sequences, and amino acids 262 to 336 of B. burgdorferi flagellin.

C. Characterization of Recombinant Flagellin 259 Fragment

In order to establish that clone pBT259 expressed the CKS-259 protein, the PBT259/XL-1 Blue culture was grown and samples were prepared as described in Example 2. Fig. 4 presents the expression of CKS-flagellin proteins in E. coli. Lane 7 contains the E. coli lysate expressing CKS-259 prior to induction and lane 8 after 3 hours of induction. The results show that the recombinant protein CKS-259 has a mobility corresponding closely to the predicted molecular mass of 35,820 daltons. Clone pBT259 also demonstrated a strong immunoreactive band at approximately 36,000 daltons with the anti-CKS sera when reacted as described in Example 2. Thus, the major protein in the pBT259 three hour induced lane on the Coomassie stained gel was the major immunoreactive product as well.

Example 7

Production and Purification of CKS-flagellin proteins

The E. coli cultures expressing recombinant flagellin proteins were grown overnight at 37°C in growth media consisting of tryptone, yeast extract, sodium chloride, glucose, tetracycline and ampicillin as described above. When the cultures reached an OD600 of 1.0, IPTG was added to a final concentration of 1 mM to induce expression. After incubation

for 4 to 16 hours, the cells were pelleted at 25,000 x g and lysed by suspension in a buffer containing 50 mM Tris, pH 8.5, 10 mM EDTA, 1 mg/ml lysozyme and 0.5% Triton X-100, followed by sonication. After centrifugation of the lysed sample, the recombinant proteins are found in the insoluble pellet. These recombinant proteins are produced in the E. coli cell as inclusion bodies, and are thus very insoluble. The soluble E. coli proteins were then removed from the insoluble protein by a series of washes in various buffers. The lysed cell pellet was first washed in Tris-EDTA buffer containing 5% Triton X-100 followed by washes of 1% sodium deoxycholate and then 0.5M sodium chloride in Tris-EDTA. After a water wash, the CKS-flagellin proteins were solubilized in 8 M urea and 1 mM DTT and analyzed by SDS-PAGE as described above in Example 2, subparagraph E. Figure 9 illustrates the purity of these proteins, Lane MW contains molucular weight standards with the sizes shown on the left. Purified p1042, p445, p410, p259, and p776 are in lanes 1 to 5 respectively.

Example 8

Diagnostic Utility of CKS-Flagellin Recombinant Proteins

Diagnostic Assay: Microtiter Plate Assay

In one embodiment of the present diagnostic assay, recombinant protein coated microtiter wells are used to capture human anti-flagellin antibody. The microtiter plate wells are incubated with 100 ul of a solution containing recombinant CKS-flagellin diluted to 1.0 to 5.0 ug/ml in 0.05 M carbonate buffer, pH 9.6. The plates are incubated in the

antigen solution for one hour at 37°C, washed in water, and overcoated in a solution consisting of 10% fetal calf serum and 3% gelatin in PBS for 30 minutes at 37°C, followed by a water wash.

Serum samples to be analyzed are diluted 1:200 in a diluent consisting of 100 mM Tris, pH 7.5, 135 mM NaCl, 10 mM EDTA, 0.2% Tween 20, 0.01% thimerosal, 4% fetal calf serum and 1% E. coli lysate. After one hour of incubation of 100 ul of the diluted sample per well at 37°C, the plate is washed three times with PBS containing 0.05% Tween 20.

Various enzyme-antibody conjugates are used to detect the presence of antibody in the sample. Goat anti-human IgG, goat anti-human IgM or goat anti-human IgG+IgM+IgA antibodies conjugated to horseradish peroxidase are typically used, but other signal generating enzymes conjugated to these antibodies are also utilized, including alkaline phosphatase and urease. These conjugates are diluted to 0.1 to 0.5 ug/ml in a diluent consisting of 100 mM Tris, pH7.5, 135 mM NaCl, 0.01% thimerosal and 10% fetal calf serum. After one hour incubation of 100 ul of the diluted conjugate per well at 37°C, the plate is washed three times with PBS containing 0.05% Tween 20. The OPD substrate solution is then added to each well and allowed to react for 5 minutes at room temperature and the reaction terminated by the addition of 1N sulfuric acid. The absorbance is then read at 490 nm.

Assay performance of the recombinant proteins with Lyme, syphilis, and normal sera.

The total antibody reactivity of representative Lyme disease positive sera or syphilis positive sera with each of the CKS-flagellin recombinant proteins was evaluated. The total antibody was detected using the goat anti-human IgG+IgM+IgA - horseradish peroxidase conjugate described above in the preceding section. The ten Lyme specimens in Figure 10 are case history defined positive patients, provided by physicians in endemic areas for Lyme disease from patients clinically diagnosed as having Lyme disease, based on dermatological, neurological, cardiac or arthritic manifestations, as defined for Lyme disease by the Centers for Disease Control.

All of these Lyme positive sera are reactive with the protein encoded by the full length flagellin clone and also are reactive with the p776 and p410 proteins, using a cut-off value of 0.2, wherein a value of less than 0.2 indicates the lack of reactivity of a polypeptide with the serum specimen tested. Reactivity with the 410 protein is generally weaker than with the full length p1042 protein, yet the p776 protein reactivity is equivalent or greater than with the full length flagellin protein. Nine of these samples were reactive with the p445 protein and seven were reactive with the p259 protein, indicating that the humoral response to the flagellin protein may encompass the entire protein.

Reactivity of these proteins with sera from syphilis positive patients is presented in Figure 11. These sera were provided by the Centers for Disease Control (CDC) and had been

determined to be positive by Rapid Plasma Reagin (PRP), Venereal Disease Research Laboratory (VDRL), and FTA-ABS (Fluorescent Treponemal Antibody Absorption) tests. These tests are routinely performed as described in Coffey and Bradford (Manual of Clinical Microbiology, 2nd Ed., 1980, Ch. 74: 530-540) Eight of the sera were reactive with the full length protein and with the amino-terminus region represented by protein p445. This is consistant with the amino acid sequence homology displayed between the B. burgdorferi and the T. pallidum flagellin proteins in this region. Four of these sera were also reactive with the carboxy-terminus p259 protein. In sharp contrast, none of the sera were reactive with the unique, non-homologous p410 or p776 proteins indicating that these are B. burgdorferi specific regions.

Evaluation of a larger population of sera, distinguishing the IgG and the IgM response, is presented in a summary fashion in Tables 1 and 2 below:

TABLE 1

Serum IgG Antibody Reactivity with CKS-Flagellin Recombinant Proteins

(Number of specimens reactive)

SPECIMEN (No.)	CKS-Flagellin Recombinant Proteins				
	p1042	p445	p410	p259	p776
Case history defined Lyme disease (25)	22	18	19	15	22
Western blot defined Lyme disease (43)	34	31	29	23	33
Syphilis positive (24)	12	10	0	6	1
Normal (37)	7	2	0	6	0

TABLE 2

Serum IgM Antibody Reactivity with CKS-Flagellin Recombinant Proteins

(Number of specimens reactive)

	CKS-Flagellin Recombinant Proteins				
SPECIMEN (No.)	p1042	p445	p410	p259	p776
Case history defined Lyme disease (16)	14	2	12	1	16
Western blot defined Lyme disease (16)	14	3	13	0	14
Syphilis positive (24)	0	0	0	0	0
Normal (37)	0	0	0	0	0

The assays for Tables 1 and 2 are as described above, with the only difference being the detection reagent used. In the IgG assay, the IgG antibody bound to the recombinant protein was detected with a goat anti-human IgG-horseradish peroxidase conjugate, while in the IgM assay the goat anti-human IgM horseradish peroxidase conjugate is used to detect the IgM antibody bound to the recombinant protein. Lyme disease positive sera were divided into two categories based on whether they were patient case history defined positive or were designated Lyme disease positive based on Western blot testing.

Western blotting for the identification of Lyme disease positive patients was similar to that described above. B. burgdorferi strain B31 was denatured in SDS/PAGE loading buffer and a volume representing 7.5 mg wet weight of cells

electrophoresed on 12% acrylamide PAGE gels. These proteins were electrophoretically transfered to nitrocellulose sheets and blocked overnight in a solution consisting of 100 mM Tris, 135 mM NaCl and 3% gelatin. Serum specimens were diluted 1:50 in the same antibody diluent as described for the microtiter plate assay and allowed to react with the nitrocellulose sheets for two hours. After washing with TBS, the antibody-antigen reactions were detected using the same conjugates, either anti-human IgG or IgM, as described above. The nitrocellulose was washed with TBS and the color developed in TBS containing 2 mg/ml 4-chloro-1-napthol, 0.02% hydrogen peroxide and 17% methanol. A serum specimen was considered positive for IgG antibody if at least five B. burgdorferi proteins were reactive, and IgM positive if at least three proteins were reactive.

The IgG antibody reactivity with the recombinant flagellin proteins (Table 1) indicates that the IgG response to flagellin was not restricted to one region, although the p776 protein was recognized by all but one serum specimen that reacted with the full-length protein. Most of the Lyme disease specimens also recognized the p410 protein. Not all of the Lyme positive sera were flagellin reactive, since, depending on the stage of infection, many Lyme patients were seronegative, or the response to the flagellin protein had waned and reactivity with other B. burgdorferi proteins occured. As predicted from the sequence homology with T. pallidum, many of the RPR positive specimens and some of the

normal sera are reactive with amino-terminus of the flagellin represented by protein p445 and with the carboxy-terminal region expressed in protein p259, as well as the full length protein. None of the syphilis positive or normal sera are reactive with the central region of the flagellin protein represented by protein p410, and only one syphilis positive sera shows reactivity with the larger p776 protein, indicating that these regions are specific for Lyme disease. The data indicate that the use of the p410 or p776 protein in an immunoassay can distinguish Lyme disease from syphilis without the use of any pre-absorption steps.

The serum IgM reactivity with the flagellin regions (Table 2) demonstrates that those regions defined by proteins p410 and p776 are most reactive. Of the Lyme disease IgM positive specimens, 30 and 25 were reactive with the p776 and p410 proteins, respectively, indicating that these proteins are useful markers for the detection of early Lyme disease. There was no cross-reactive IgM antibody to any of the flagellin proteins in the syphilis or the normal sera tested. In the case of detection of IgM antibody, the p776 and p410 proteins are far superior to either end of the flagellin protein, indicating that the earliest response in humans to flagellin is elicited by the central unique region.

Deposit

The recombinant transfer vectors pB410 and pB776 in E. coli K-12 have been deposited under the Budapest Treaty, at the American Type Culture Collection, Rockville, MD 20852 (U.S.A.)

on October 3, 1991 under the respective ATCC Nos. 68724 and 68725.

Availability of the deposited strains is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

Also, the present invention is not to be considered limited in scope by the deposited recombinant transfer vectors, since the deposited vectors are intended only to be illustrative of particular aspects of the invention. Any recombinant transfer vector which can be used to prepare recombinant microorganism which can function to produce a recombinant protein product is considered to be within the scope of this invention. Further, various modifications of the invention in addition to those shown and described herein which are apparent to those skilled in the art from the preceding description are considered to fall within the scope of the appended claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Robinson, John M
Pilot-Matias, Tami J
Hunt, Jeffrey C

(ii) TITLE OF INVENTION: Borrelia burgdorferi antigens and uses thereof

(iii) NUMBER OF SEQUENCES: 16

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Abbott Laboratories
(B) STREET: One Abbott Park Road
(C) CITY: Abbott Park
(D) STATE: Illinois
(E) COUNTRY: USA
(F) ZIP: 60064

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US
(B) FILING DATE: 21-OCT-1991 (U.S. priority date)
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Wong, Wean Khing
(B) REGISTRATION NUMBER: 33561
(C) REFERENCE/DOCKET NUMBER: 5051.PC.01

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 708-937-9396
(B) TELEFAX: 708-937-9556

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1497 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Borrelia burgdorferi
(B) STRAIN: B31

(vii) IMMEDIATE SOURCE:
(B) CLONE: pB776

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATGAGTTTTG TGGTCATTAT TCCCGCGCGC TACGCGTCGA CGCGTCTGCC 50

CGGTAAACCA TTGGTTGATA TTAACGGCAA ACCCATGATT GTTCATGTTC 100

TTGAACGCGC GCGTGAATCA GGTGCCGAGC GCATCATCGT GGCAACCGAT 150

CATGAGGATG TTGCCCGCGC CGTTGAAGCC GCTGGCGGTG AAGTATGTAT 200

GACGCGCGCC GATCATCAGT CAGGAACAGA ACGTCTGGCG GAAGTTGTCG 250

AAAAATGCGC ATTCAGCGAC GACACGGTGA TCGTTAATGT GCAGGGTGAT 300

GAACCGATGA TCCCTGCGAC AATCATTCGT CAGGTTGCTG ATAACCTCGC 350

TCAGCGTCAG GTGGGTATGG CGACTCTGGC GGTGCCAATC CACAATGCGG 400

AAGAAGCGTT TAACCCGAAT GCGGTGAAAG TGGTTCTCGA CGCTGAAGGG 450

TATGCACTGT ACTTCTCTCG CGCCACCATT CCTTGGGATC GTGATCGTTT 500

TGCAGAAGGC CTTGAAACCG TTGGCGATAA CTTCCTGCGT CATCTTGGTA 550

TTTATGGCTA CCGTGCAGGC TTTATCCGTC GTTACGTCAA CTGGCAGCCA 600

AGTCCGTTAG AACACATCGA AATGTTAGAG CAGCTTCGTG TTCTGTGGTA 650

CGGCGAAAAA ATCCATGTTG CTGTTGCTCA GGAAGTTCCT GGCACAGGTG 700

TGGATACCCC TGAAAATCCG TCGACAGGGC TTATGAAGAT CTCAGACCCG 750

AGAAATACTT CAAAGGCTAT TAATTTTATT CAGACAACAG AAGGGAATTT 800

AAATGAAGTA GAAAAAGTCT TAGTAAGAAT GAAGGAATTG GCAGTTCAAT 850

CAGGTAACGG CACATATTCA GATGCAGACA GAGGTTCTAT ACAAATTGAA 900

ATAGAGCAAC TTACAGACGA AATTAATAGA ATTGCTGATC AAGCTCAATA 950

TAACCAAATG CACATGTTAT CAAACAAATC TGCTTCTCAA AATGTAAGAA 1000

CAGCTGAAGA GCTTGGAATG CAGCCTGCAA AAATTAACAC ACCAGCATCG 1050

CTTTCAGGGT CTCAAGCGTC TTGGACTTTA AGAGTTCATG TTGGAGCAAA 1100

CCAAGATGAA GCTATTGCTG TAAATATTTA TGCAGCTAAT GTTGCAAATC 1150

TTTTCTCTGG TGAGGGAGCT CAAACTGCTC AGGCTGCACC GGTTCAAGAG 1200

GGTGTTCAAC AGGAAGGAGC TCAACAGCCA GCACCTGCTA CAGCACCTTC 1250

TCAAGGCGGA GTTAATTCTC CTGTTAATGT TACAACTACA GTTGATGCTA 1300

ATACATCACT TGCTAAAATT GAAAATGCTA TTAGAATGAT AAGTGATCAA 1350

AGAGCAAATT TAGGTGCTTT CCAAAATAGA CTTGAATCTA TAAAGGATAG 1400

TACTGAGTAT GCAATTGAAA ATCTAAAAGC ATCTTATGCT CAAATAAAAG 1450

ATGCTACAAT GACAGATGAG GTTGTAGCAG CAACAACTAA TAGTTAA 1497

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 498 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Borrelia burgdorferi
(B) STRAIN: B31

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ser Phe Val Val Ile Ile Pro Ala Arg Tyr Ala Ser Thr Arg
1 5 10 15

Leu Pro Gly Lys Pro Leu Val Asp Ile Asn Gly Lys Pro Met Ile

20 25 30

Val His Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg Ile
35 40 45

Ile Val Ala Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala
50 55 60

Ala Gly Gly Glu Val Cys Met Thr Arg Ala Asp His Gln Ser Gly
65 70 75

Thr Glu Arg Leu Ala Glu Val Val Glu Lys Cys Ala Phe Ser Asp
80 85 90

Asp Thr Val Ile Val Asn Val Gln Gly Asp Glu Pro Met Ile Pro
95 100 105

Ala Thr Ile Ile Arg Gln Val Ala Asp Asn Leu Ala Gln Arg Gln
110 115 120

Val Gly Met Ala Thr Leu Ala Val Pro Ile His Asn Ala Glu Glu
125 130 135

Ala Phe Asn Pro Asn Ala Val Lys Val Val Leu Asp Ala Glu Gly
140 145 150

Tyr Ala Leu Tyr Phe Ser Arg Ala Thr Ile Pro Trp Asp Arg Asp
155 160 165

Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp Asn Phe Leu Arg
170 175 180

His Leu Gly Ile Tyr Gly Tyr Arg Ala Gly Phe Ile Arg Arg Tyr
185 190 195

Val Asn Trp Gln Pro Ser Pro Leu Glu His Ile Glu Met Leu Glu
200 205 210

Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys Ile His Val Ala Val
215 220 225

Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asn Pro
230 235 240

Ser Thr Gly Leu Met Lys Ile Ser Asp Pro Arg Asn Thr Ser Lys
245 250 255

Ala Ile Asn Phe Ile Gln Thr Thr Glu Gly Asn Leu Asn Glu Val
260 265 270

Glu Lys Val Leu Val Arg Met Lys Glu Leu Ala Val Gln Ser Gly

275 280 285

Asn Gly Thr Tyr Ser Asp Ala Asp Arg Gly Ser Ile Gln Ile Glu
290 295 300

Ile Glu Gln Leu Thr Asp Glu Ile Asn Arg Ile Ala Asp Gln Ala
305 310 315

Gln Tyr Asn Gln Met His Met Leu Ser Asn Lys Ser Ala Ser Gln
320 325 330

Asn Val Arg Thr Ala Glu Glu Leu Gly Met Gln Pro Ala Lys Ile
335 340 345

Asn Thr Pro Ala Ser Leu Ser Gly Ser Gln Ala Ser Trp Thr Leu
350 355 360

Arg Val His Val Gly Ala Asn Gln Asp Glu Ala Ile Ala Val Asn
365 370 375

Ile Tyr Ala Ala Asn Val Ala Asn Leu Phe Ser Gly Glu Gly Ala
380 385 390

Gln Thr Ala Gln Ala Ala Pro Val Gln Glu Gly Val Gln Gln Glu
395 400 405

Gly Ala Gln Gln Pro Ala Pro Ala Thr Ala Pro Ser Gln Gly Gly
410 415 420

Val Asn Ser Pro Val Asn Val Thr Thr Thr Val Asp Ala Asn Thr
425 430 435

Ser Leu Ala Lys Ile Glu Asn Ala Ile Arg Met Ile Ser Asp Gln
440 445 450

Arg Ala Asn Leu Gly Ala Phe Gln Asn Arg Leu Glu Ser Ile Lys
455 460 465

Asp Ser Thr Glu Tyr Ala Ile Glu Asn Leu Lys Ala Ser Tyr Ala
470 475 480

Gln Ile Lys Asp Ala Thr Met Thr Asp Glu Val Val Ala Ala Thr
485 490 495

Thr Asn Ser

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 747 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Borrelia burgdorferi
(B) STRAIN: B31

(vii) IMMEDIATE SOURCE:
(B) CLONE: 776

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AGAAATACTT CAAAGGCTAT TAATTTTATT CAGACAACAG AAGGGAATTT 50

AAATGAAGTA GAAAAAGTCT TAGTAAGAAT GAAGGAATTG GCAGTTCAAT 100

CAGGTAACGG CACATATTCA GATGCAGACA GAGGTTCTAT ACAAATTGAA 150

ATAGAGCAAC TTACAGACGA AATTAATAGA ATTGCTGATC AAGCTCAATA 200

TAACCAAATG CACATGTTAT CAAACAAATC TGCTTCTCAA AATGTAAGAA 250

CAGCTGAAGA GCTTGGAATG CAGCCTGCAA AAATTAACAC ACCAGCATCG 300

CTTTCAGGGT CTCAAGCGTC TTGGACTTTA AGAGTTCATG TTGGAGCAAA 350

CCAAGATGAA GCTATTGCTG TAAATATTTA TGCAGCTAAT GTTGCAAATC 400

TTTTCTCTGG TGAGGGAGCT CAAACTGCTC AGGCTGCACC GGTTCAAGAG 450

GGTGTTCAAC AGGAAGGAGC TCAACAGCCA GCACCTGCTA CAGCACCTTC 500

TCAAGGCGGA GTTAATTCTC CTGTTAATGT TACAACTACA GTTGATGCTA 550

ATACATCACT TGCTAAAATT GAAAATGCTA TTAGAATGAT AAGTGATCAA 600

AGAGCAAATT TAGGTGCTTT CCAAAATAGA CTTGAATCTA TAAAGGATAG 650

TACTGAGTAT GCAATTGAAA ATCTAAAAGC ATCTTATGCT CAAATAAAAG 700

ATGCTACAAT GACAGATGAG GTTGTAGCAG CAACAACTAA TAGTTAA 747

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 248 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Borrelia burgdorferi
(B) STRAIN: B31

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```
Arg Asn Thr Ser Lys Ala Ile Asn Phe Ile Gln Thr Thr Glu Gly
1               5                  10                  15

Asn Leu Asn Glu Val Glu Lys Val Leu Val Arg Met Lys Glu Leu
            20                  25                  30

Ala Val Gln Ser Gly Asn Gly Thr Tyr Ser Asp Ala Asp Arg Gly
        35                  40                  45

Ser Ile Gln Ile Glu Ile Glu Gln Leu Thr Asp Glu Ile Asn Arg
    50                  55                  60

Ile Ala Asp Gln Ala Gln Tyr Asn Gln Met His Met Leu Ser Asn
65                  70                  75

Lys Ser Ala Ser Gln Asn Val Arg Thr Ala Glu Glu Leu Gly Met
                80                  85                  90

Gln Pro Ala Lys Ile Asn Thr Pro Ala Ser Leu Ser Gly Ser Gln
            95                  100                 105

Ala Ser Trp Thr Leu Arg Val His Val Gly Ala Asn Gln Asp Glu
        110                 115                 120

Ala Ile Ala Val Asn Ile Tyr Ala Ala Asn Val Ala Asn Leu Phe
    125                 130                 135

Ser Gly Glu Gly Ala Gln Thr Ala Gln Ala Ala Pro Val Gln Glu
140                 145                 150
```

Gly Val Gln Gln Glu Gly Ala Gln Gln Pro Ala Pro Ala Thr Ala
155 160 165

Pro Ser Gln Gly Gly Val Asn Ser Pro Val Asn Val Thr Thr Thr
170 175 180

Val Asp Ala Asn Thr Ser Leu Ala Lys Ile Glu Asn Ala Ile Arg
185 190 195

Met Ile Ser Asp Gln Arg Ala Asn Leu Gly Ala Phe Gln Asn Arg
200 205 210

Leu Glu Ser Ile Lys Asp Ser Thr Glu Tyr Ala Ile Glu Asn Leu
215 220 225

Lys Ala Ser Tyr Ala Gln Ile Lys Asp Ala Thr Met Thr Asp Glu
230 235 240

Val Val Ala Ala Thr Thr Asn Ser
245

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1131 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Borrelia burgdorferi
(B) STRAIN: B31

(vii) IMMEDIATE SOURCE:
(B) CLONE: pb410

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATGAGTTTTG TGGTCATTAT TCCCGCGCGC TACGCGTCGA CGCGTCTGCC 50

CGGTAAACCA TTGGTTGATA TTAACGGCAA ACCCATGATT GTTCATGTTC 100

TTGAACGCGC GCGTGAATCA GGTGCCGAGC GCATCATCGT GGCAACCGAT 150

CATGAGGATG TTGCCCGCGC CGTTGAAGCC GCTGGCGGTG AAGTATGTAT 200

GACGCGCGCC GATCATCAGT CAGGAACAGA ACGTCTGGCG GAAGTTGTCG 250

AAAAATGCGC ATTCAGCGAC GACACGGTGA TCGTTAATGT GCAGGGTGAT 300

GAACCGATGA TCCCTGCGAC AATCATTCGT CAGGTTGCTG ATAACCTCGC 350

TCAGCGTCAG GTGGGTATGG CGACTCTGGC GGTGCCAATC CACAATGCGG 400

AAGAAGCGTT TAACCCGAAT GCGGTGAAAG TGGTTCTCGA CGCTGAAGGG 450

TATGCACTGT ACTTCTCTCG CGCCACCATT CCTTGGGATC GTGATCGTTT 500

TGCAGAAGGC CTTGAAACCG TTGGCGATAA CTTCCTGCGT CATCTTGGTA 550

TTTATGGCTA CCGTGCAGGC TTTATCCGTC GTTACGTCAA CTGGCAGCCA 600

AGTCCGTTAG AACACATCGA AATGTTAGAG CAGCTTCGTG TTCTGTGGTA 650

CGGCGAAAAA ATCCATGTTG CTGTTGCTCA GGAAGTTCCT GGCACAGGTG 700

TGGATACCCC TGAAAATCCG TCGACAGGGC TTATGAAGAT CTCAGACCCG 750

TCAAACAAAT CTGCTTCTCA AAATGTAAGA ACAGCTGAAG AGCTTGGAAT 800

GCAGCCTGCA AAAATTAACA CACCAGCATC GCTTTCAGGG TCTCAAGCGT 850

CTTGGACTTT AAGAGTTCAT GTTGGAGCAA ACCAAGATGA AGCTATTGCT 900

GTAAATATTT ATGCAGCTAA TGTTGCAAAT CTTTTCTCTG GTGAGGGAGC 950

TCAAACTGCT CAGGCTGCAC CGGTTCAAGA GGGTGTTCAA CAGGAAGGAG 1000

CTCAACAGCC AGCACCTGCT ACAGCACCTT CTCAAGGCGG AGTTAATTCT 1050

CCTGTTAATG TTACAACTAC AGTTGATGCT AATACATCAC TTGCTAAAAT 1100

TGAAAATGCT ATTAGAATGA TAAGTGATTA A 1131

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 376 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Borrelia burgdorferi
(B) STRAIN: B31

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Ser Phe Val Val Ile Ile Pro Ala Arg Tyr Ala Ser Thr Arg
1 5 10 15

Leu Pro Gly Lys Pro Leu Val Asp Ile Asn Gly Lys Pro Met Ile
20 25 30

Val His Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg Ile
35 40 45

Ile Val Ala Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala
50 55 60

Ala Gly Gly Glu Val Cys Met Thr Arg Ala Asp His Gln Ser Gly
65 70 75

Thr Glu Arg Leu Ala Glu Val Val Glu Lys Cys Ala Phe Ser Asp
80 85 90

Asp Thr Val Ile Val Asn Val Gln Gly Asp Glu Pro Met Ile Pro
95 100 105

Ala Thr Ile Ile Arg Gln Val Ala Asp Asn Leu Ala Gln Arg Gln
110 115 120

Val Gly Met Ala Thr Leu Ala Val Pro Ile His Asn Ala Glu Glu
125 130 135

Ala Phe Asn Pro Asn Ala Val Lys Val Val Leu Asp Ala Glu Gly
140 145 150

Tyr Ala Leu Tyr Phe Ser Arg Ala Thr Ile Pro Trp Asp Arg Asp
155 160 165

Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp Asn Phe Leu Arg
170 175 180

His Leu Gly Ile Tyr Gly Tyr Arg Ala Gly Phe Ile Arg Arg Tyr
185 190 195

```
Val Asn Trp Gln Pro Ser Pro Leu Glu His Ile Glu Met Leu Glu
                200                 205                 210

Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys Ile His Val Ala Val
                215                 220                 225

Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asn Pro
                230                 235                 240

Ser Thr Gly Leu Met Lys Ile Ser Asp Pro Ser Asn Lys Ser Ala
                245                 250                 255

Ser Gln Asn Val Arg Thr Ala Glu Glu Leu Gly Met Gln Pro Ala
                260                 265                 270

Lys Ile Asn Thr Pro Ala Ser Leu Ser Gly Ser Gln Ala Ser Trp
                275                 280                 285

Thr Leu Arg Val His Val Gly Ala Asn Gln Asp Glu Ala Ile Ala
                290                 295                 300

Val Asn Ile Tyr Ala Ala Asn Val Ala Asn Leu Phe Ser Gly Glu
                305                 310                 315

Gly Ala Gln Thr Ala Gln Ala Ala Pro Val Gln Glu Gly Val Gln
                320                 325                 330

Gln Glu Gly Ala Gln Gln Pro Ala Pro Ala Thr Ala Pro Ser Gln
                335                 340                 345

Gly Gly Val Asn Ser Pro Val Asn Val Thr Thr Thr Val Asp Ala
                350                 355                 360

Asn Thr Ser Leu Ala Lys Ile Glu Asn Ala Ile Arg Met Ile Ser
                365                 370                 375

Asp
```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 381 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Borrelia burgdorferi
(B) STRAIN: B31

(vii) IMMEDIATE SOURCE:
(B) CLONE: 410

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TCAAACAAAT CTGCTTCTCA AAATGTAAGA ACAGCTGAAG AGCTTGGAAT 50

GCAGCCTGCA AAAATTAACA CACCAGCATC GCTTTCAGGG TCTCAAGCGT 100

CTTGGACTTT AAGAGTTCAT GTTGGAGCAA ACCAAGATGA AGCTATTGCT 150

GTAAATATTT ATGCAGCTAA TGTTGCAAAT CTTTTCTCTG GTGAGGGAGC 200

TCAAACTGCT CAGGCTGCAC CGGTTCAAGA GGGTGTTCAA CAGGAAGGAG 250

CTCAACAGCC AGCACCTGCT ACAGCACCTT CTCAAGGCGG AGTTAATTCT 300

CCTGTTAATG TTACAACTAC AGTTGATGCT AATACATCAC TTGCTAAAAT 350

TGAAAATGCT ATTAGAATGA TAAGTGATTA A 381

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 126 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Protein

(iii) HYPOTHETICAL:

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: interval

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Borrelia burgdorferi
(B) STRAIN: B31

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Ser Asn Lys Ser Ala Ser Gln Asn Val Arg Thr Ala Glu Glu Leu

1 5 10 15

Gly Met Gln Pro Ala Lys Ile Asn Thr Pro Ala Ser Leu Ser Gly
20 25 30

Ser Gln Ala Ser Trp Thr Leu Arg Val His Val Gly Ala Asn Gln
35 40 45

Asp Glu Ala Ile Ala Val Asn Ile Tyr Ala Ala Asn Val Ala Asn
50 55 60

Leu Phe Ser Gly Glu Gly Ala Gln Thr Ala Gln Ala Ala Pro Val
65 70 75

Gln Glu Gly Val Gln Gln Glu Gly Ala Gln Gln Pro Ala Pro Ala
80 85 90

Thr Ala Pro Ser Gln Gly Gly Val Asn Ser Pro Val Asn Val Thr
95 100 105

Thr Thr Val Asp Ala Asn Thr Ser Leu Ala Lys Ile Glu Asn Ala
110 115 120

Ile Arg Met Ile Ser Asp
125

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Borrelia burgdorferi
(B) STRAIN: B31

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AAATAGATCT CAGACCCGAG AAATACTTCA AAGGCTAT 38

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Borrelia burgdorferi
(B) STRAIN: B31

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GGGCAAGCTT ATTAACTATT AGTTGTTGCT GCTAC 35

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Borrelia burgdorferi
(B) STRAIN: B31

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

AAATAGATCT CAGACCCGTC AAACAAATCT GCTTCTCA 38

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Borrelia burgdorferi
(B) STRAIN: B31

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GGGCAAGCTT ATTAATCACT TATCATTCTA ATAG 34

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Borrelia burgdorferi
(B) STRAIN: B31

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

AAATAGATCT CAGACCCGAT GATTATCAAT CATAATAC 38

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Borrelia burgdorferi
(B) STRAIN: B31

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GGGCGGTACC TTATTATCTA AGCAATGACA AAAC 34

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Borrelia burgdorferi
(B) STRAIN: B31

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GGGCGGTACC TTATTATGAT AACATGTGCA TTTGGTT 37

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Borrelia burgdorferi
(B) STRAIN: B31

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

AAATAGATCT CAGACCCGGA TCAAAGGGCA AATTTAGG 38

CLAIMS

We Claim:

1. A non-naturally occuring polypeptide which does not substantially bind an antibody to T. pallidum, comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 8, and equivalent polypeptides thereof.

2. A non-naturally occuring polypeptide which does not substantially bind an antibody to T. pallidum, comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, and equivalent polypeptides thereof.

3. A polypeptide comprising a fragment of the amino acid sequence of claims 1 or 2, wherein said fragment retains the ability to bind an antibody to B. burgdorferi and to differentiate between the antibody to B. burgdorferi and the antibody to T. pallidum.

4. A polypeptide comprising a sequence which is recognized by an antibody which binds an amino acid sequence selected from the group consisting of SEQ ID NO: 4 and SEQ ID NO: 8; wherein said polypeptide does not substantially bind an antibody to T. pallidum.

5. The polypeptide of claim 1, 2, 3, or 4, produced recombinantly.

6. The polypeptide of claim 5 produced by a host selected from the group consisting of plant, bacterial, yeast, insect, and mammalian.

7. The polypeptide of claim 6 produced by E. coli.

8. The polypeptide of claim 1 wherein the polypeptide is defined by SEQ ID NO: 4 or SEQ ID NO: 8.

9. Recombinant fusion protein p776.

10. Recombinant fusion protein p410.

11. A nucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 7, and equivalent nucleotide sequences thereof.

12. The nucleotide sequence of claim 11, wherein the nucleotide sequence comprises nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 5, and equivalent nucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 5.

13. A fragment of the nucleotide sequence of claim 11 which encodes a polypeptide which is immunoreactive with an antibody to B. burgdorferi , but which is not substantially immunoreactive with an antibody to T. pallidum.

14. A vector comprising the nucleotide sequence selected from the nucleotide sequences of claims 11 and 13.

15. Plasmid pB776.

16. Plasmid PB410.

17. A host transformed by the nucleotide sequence of claim 11 or 13.

18. The transformed cell of claim 17, selected from the group consisting of plant, bacteria, yeast, insect, and mammal.

19. A transformed cell capable of producing the polypeptide of claim 1, 2, 3, or 4.

20. The transformed cell of claim 19, selected from the group consisting of plant, bacteria, yeast, insect, and mammal.

21. Transformed E.coli designated ATCC No. 68724 or ATCC No. 68725.

22. A method for differentiating between antibody to B. burgdorferi and antibody to T. pallidum in a test sample, comprising the steps of:

a) Incubating the test sample with a differentiating polypeptide which binds antibody to B. burgdorferi but which does not substantially bind antibody to T. pallidum, for a sufficient time for antibody to bind to the differentiating polypeptide to form an antibody-differentiating polypeptide conjugate; and

b) detecting the antibody-differentiating polypeptide conjugate.

23. The method of claim 22, wherein the differentiating polypeptide comprises a non-naturally occuring polypeptide sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 4, and equivalent polypeptides thereof.

24. The method of claim 22, wherein the differentiating polypeptide comprises a polypeptide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, and equivalent polypeptides of SEQ ID NO: 2 and SEQ ID NO: 6.

25. The method of claim 22, wherein the differentiating polypeptide is bound to a solid support.

26. The method of claim 22, wherein the solid support comprises a material selected from the group consisting of polystyrene, paper, or nitrocellulose.

27. An antibody capture assay for identifying the presence of a first antibody of the IgM or IgG class which is immunologically reactive with a B. burgdorferi antigen in a fluid sample comprising the steps of:

a) contacting the fluid sample with a solid support containing a bound second antibody, said second antibody being capable of binding to a mu-chain of an IgM antibody or gamma-chain of an IgG antibody, under conditions suitable for complexing the second antibody with the IgM or IgG antibody found in the fluid sample;

b) contacting an immunoreactive polypeptide to the solid support, wherein the immunoreactive polypeptide is immunoreactive with the first antibody, under conditions suitable for complexing the first antibody to the immunoreactive polypeptide,

c) contacting a third antibody to the solid support, wherein said third antibody is immunoreactive with the immunoreactive polypeptide, under conditions suitable for complexing of the third antibody to the immunoreactive polypeptide,

d) detecting complex of (second antibody-IgM or IgG antibody-immunoreactive polypeptide-third antibody), the presence of the complex indicating the presence of the first antibody,

wherein the immunoreactive polypeptide comprises the polypeptide of claim 1, 2, 3, or 4.

28. The method of claim 27, wherein the third antibody is labelled for detection purpose.

29. An antibody capture assay for identifying the presence of a first antibody of the IgM or IgG class which is immunologically reactive with a B. burgdorferi antigen in a fluid sample, comprising the steps of:

a) contacting the fluid sample with a solid support containing a bound second antibody, said second antibody being capable of binding to a mu-chain of an IgM antibody or gamma-chain of an IgG antibody, under conditions suitable for complexing the second antibody with the IgM or IgG antibody found in the fluid sample;

b) contacting an immunoreactive polypeptide to the solid support, wherein the immunoreactive polypeptide is immunoreactive with the first antibody, under conditions suitable for complexing the first antibody to the immunoreactive polypeptide,

c) detecting complex of (second antibody-IgM or IgG antibody- immunoreactive polypeptide), the presence of the complex indicating the presene of the first antibody,

wherein the immunoreactive polypeptide comprises the polypeptide of claim 1, 2, 3, or 4.

30. the method of claim 29, wherein the immunoreactive polylpeptide is labelled for detection.

31. An immunodot assay for identifying the presence of an antibody immunologically reactive with a B. burgdorferi

antigen in a fluid sample wherein the sample is contacted with an imunoreactive polypeptide bound to the solid support under conditions suitable for complexing the antibody with the immunoreactive polypeptide; and detecting the antibody-immunoreactive polypeptide complex, wherein the immunoreactive polypeptide comprises the polypeptides of claims 1, 2, 3, or 4.

32. The assay of claim 31, wherein the solid support comprises a material selected from the group consisting of nitrocellulose or paper.

33. An immunoassay kit comprising: a first container containing antigen selected from the group consisting of the polypeptides of claims 1, 2, 3, 4 and combinations thereof, in a concentration suitable for use in an immunoassay.

34. The immunoassay kit of claim 33, further comprising a second container containing one or more detection or signal producing reagents.

35. The immunoassay kit of claim 34, further comprising a third container containing one ore more sample preparation reagents.

36. The kit of claim 33, wherein the polypeptide is bound to a solid support.

37. A process for producing an antigen specific for B. burgdorferi, comprising the steps of:

a) introducing into a host a vector containing a nucleotide sequence coding for the antigen, said nucleotide sequence is selected from the group consisting of nucleotide sequences of claim 11 or 13,

b) culturing the transformed host, and

c) harvesting the antigen produced by the transformed host.

38. A non-naturally occurring antibody to the polypeptides of claims 1, 2, 3, or 4.

39. The polypeptide of claims 1, 2, 3, or 4 which is labelled.

40. The method of claim 22, wherein the solid support comprises bead or microparticle.

```
FLA$BORBU - MIINHNTSAINASRNNGINAANLSKTQEKLSSGYRINRASDDAAGMGVSG -50
            ****** **    *  *        *  ****** ****  *** *  **
TRPPAFLAB2- MIINHNMSAMFSQRTLGHTNLSVQKNIEKLSSGLRINRSGDDASGLAVSE -50

FLA$BORBU - KINAQIRGLSQASRNTSKAINFIQTTEGNLNEVEKVLVRMKELAVQSGNG -100
            *   ***** *** *    * ***  *  * *   *  *  ** **  **
TRPPAFLAB2- KMRSQIRGLNQASTNAQNGISFIQVAEAFLQETTDVIQRIRELSVQAANG -100

FLA$BORBU - TYSDADRGSIQIEIEQLTDEINRIADQAQYNQMHMLSNKSASQNVRTAEE -150
             **  **  ** *  **  *  ***  ** * * **    * *
TRPPAFLAB2- IYSAEDRLYIQVEVSQLVAEVDRIASHAQFNGMNMLTGRFARQG------ -144

FLA$BORBU - LGMQPAKINTPASLSGSQASWTLRVHVGANQDEAIAVNIYAANVANLFSG -200
                                      * *** *      *
TRPPAFLAB2- --------------GENTVTASMWFHIGANMDQRTRAYIGTMTAV----- -175
```

FIG. 1A


FLA$BORBU - EGAQTAQAAPVQEGVQQEGAQQPAPATAPSQGGVNSPVNVTTTVDANTSL -250
TRPPAFLAB2- ----------AMGIRDAGDESVMNIDSPEKANRAI -200
FLA$BORBU - AKIENAIRMISDQRANLGAFQNRLESIKDSTEYAIENLKASYAQIKDATM -300
TRPPAFLAB2- GTLDQAIKRINKQRADLGAYQNRLDHTVAGINVAAENLQAAESRIRDVDM -250
FLA$BORBU - TDEVVAATTNSILTQSAMAMIAQANQVPQYVLSLLR -336
TRPPAFLAB2- AKEMVDYTKNQILVQSGTAMLAQANQATQSVLSLLR -286

FIG.1B


BORRELIA BURGDORFERI FLAGELLIN
Treponema pallidum flagellin
1
336
pB1042
1
136
pB445
137
262
pB410
263
336
pB259
64
311
pB776

FIG. 2


B. burgdorferi Genomic DNA
Primers
Sense: 5' AAATAGATCTCAGACCCGAGAAATACTTCAAAGGCTAT 3'
Antisense: 5' GGGCAAGCTTATTAACTATTAGTTGTTGCTGCTAC 3'
PCR Amplify
(using "tailed" primers)
776 bp Fla Fragment
BglII
Hind III
Digest with
BglII & Hind III
LIGATION
CKS
BglII
Hind III
pTPM 210
Digest with
BglII & Hind III
CKS
776
pB776

FIG. 3


MW 1 2 3 4 5 6 7 8 9 10
97–
66–
45–
31–
21–
14–
pBT1042
pB776
pB410
pBT445
pBT259

FIG. 4


B. burgdorferi Genomic DNA
Primers
Sense: 5' AAATAGATCTCAGACCCGTCAAACAAATCTGCTTCTCA 3'
Antisense: 5' GGGCAAGCTTATTAATCACTTATCATTCTAATAG 3'
PCR Amplify
(using "tailed" primers)
410 bp Fla Fragment
BglII
HindIII
Digest with
BglII & HindIII
LIGATION
CKS
BglII
HindIII
pTPM210
Digest with
BglII & HindIII
CKS
410
pB 410

FIG. 5


B. burgdorferi Genomic DNA
Primers
Sense: 5' AAATAGATCTCAGACCCGATGATTATCAATCATAATAC 3'
Antisense: 5' GGGCGGTACCTTATTATCTAAGCAATGACAAAAC 3'
PCR Amplify
(using "tailed" primers)
1042 bp Fla Fragment
BglII
KpnI
Digest with
BglII & KpnI
LIGATION
CKS
BglII
KpnI
pTB210
Digest with
BglII & KpnI
CKS
1042
pBT1042

FIG. 6


B. burgdorferi Genomic DNA
Primers
Sense: 5' AAATAGATCTCAGACCCGATGATTATCAATCATAATAC 3'
Antisense: 5' GGGCGGTACCTTATTATGATAACATGTGCATTTGGTT 3'
PCR Amplify
(using "tailed" primers)
445 bp Fla Fragment
BglII
KpnI
Digest with
BglII & KpnI
LIGATION
CKS
BglII
KpnI
pTB210
Digest with
BglII & KpnI
CKS
445
pBT445

FIG. 7


B. burgdorferi Genomic DNA
Primers
Sense: 5' AAATAGATCTCAGACCCGGATCAAAGGGCAAATTTAGG 3'
Antisense: 5' GGGCGGTACCTTATTATCTAAGCAATGACAAAAC 3'
PCR Amplify
(using "tailed" primers)
259 bp Fla Fragment
BglII
KpnI
Digest with
BglII & KpnI
LIGATION
CKS
BglII
KpnI
pTB210
Digest with
BglII & KpnI
CKS
259
pBT259

FIG. 8



FIG. 9


ABSORBANCE
2
1.5
1
0.5
0.2
0
1
2
3
4
5
6
7
8
9
10
PATIENT
1042
445
410
259
776

FIG. 10


ABSORBANCE
1
0.8
0.6
0.4
0.2
0
1
2
3
4
5
6
7
8
9
10
PATIENT
1042
445
410
259
776

FIG. 11

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/09199

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :Please See Extra Sheet.
US CL :Please See Extra Sheet.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/7.32, 7.92, 69.3, 240.1, 252.3, 320.1; 436/513, 518, 530, 536, 540, 541, 542, 544; 530/300, 350, 387, 825; 536/27

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	Journal of Bacteriology, Volume 173, No. 4, issued February 1991, G.S. Gassmann et al., "Analysis of the Borrelia burdorferi GeHo Gene Fla and Antigenic Characterization of Its Gene Product", pages 1452-1459, especially figures 1, 4, 5, 6 and 7.	1-7, 11-14, 17-20, 38-39 ——— 9-10, 15-16, 21-37, 40
X Y	Infection and Immunity, Volume 52, No. 5, issued May 1986, A.G. Barbour et al., "A Borrelia- Specific Monoclonal Antibody Binds to a Flagellar Epitope", pages 549-554, especially Table 1.	1-7, 38-39 —— 8-37, 40

[X] Further documents are listed in the continuation of Box C. [ ] See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be part of particular relevance

"E" earlier document published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
12 January 1993	26 JAN 1993
Name and mailing address of the ISA/ Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. NOT APPLICABLE	Authorized officer GABRIELE E. BUGAISKY Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/09199

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	Nucleic Acids Research, Volume 17, No. 9, issued 1989, G.S. Gassmann et al., "Nucleotide sequence of a gene encoding the Borrelia burgdorferi flagellin, page 3590, entire document.	11-12, 14, 17-20, ——— 1-10, 13, 15-16, 21-40
X Y	Infection and Immunity, Volume 59, No. 10, issued October 1991, R. Berland et al., "Molecular Characterization of the Humoral Response to the 41-Kilodalton Flagellar Antigen of Borrelia burgdorferi, the Lyme Diesease Agent", pages 3531-3535, entire document.	1-8, 11-14, 17-20, 29,37-39 ——— 9-10, 15-16, 21-28, 30-36, 40
X Y	Infection and Immunity, Volume 58, No. 6, issued June 1990, R. Wallich et al., "The Borrelia burgdorferi Flagellum-Associated 41-Kilodalton Antigen (Flagellin): Molecular Cloning, Expression, and Amplification of the Gene", pages 1711-1719, entire document.	1-7, 11-12, 14, 17-20, 37-39 ——— 8-10, 13, 15-16, 21-36, 40
X Y	Infection and Immunity, Volume 59, No. 2, issued, February 1991, C. Collins et al., "Immunoreactive Epitopes on an Expresed Recombinant Flagellar Protein of Borrelia burgdorferi", pages 512-520, entire document.	1-7, 11-12, 14, 17-20, 37-39 ——— 8-10, 13, 15-16 21-36, 40

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/09199

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (5):

C07H 21/00; C07K 3/00, 5/04, 7/52, 13/00, 15/06; C12N 5/10, 5/21, 5/31; C12P 21/02; G01N 33/53, 33/532, 33/536, 33/537, 33/538, 33/541, 33/543, 33/544, 33/68

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

435/7.32, 7.92, 69.3, 240.1, 252.3, 320.1; 436/513, 518, 530, 536, 540, 541, 542, 544; 530/300, 350, 387; 536/27

B. FIELDS SEARCHED
Electronic data bases consulted (Name of data base and where practicable terms used):

Genbank, EMBL, SwissProt, PIR, APS, Dialog files 155, 5, 73, 357 (Medline, Biosis, Embase, Biotech Abstracts)
search terms: borrelia, borelia, flagell?, lyme, polypeptide(s), flagellin, burgdorfer?,